Richardson et al
Lung diseases are a leading cause of death yet only 3% of new inhaled medications reach the market. The COVID-19 pandemic has highlighted the need for more efficient therapeutic evaluation.
Traditional 2D cell models are cost-effective but not physiologically relevant, whereas animal models are costly, time-consuming and not human representative.
Here, we demonstrate the potential of two lung MPS models (alveolar and bronchial) to accurately mimic two parts of the lung that are key to better and more robust preclinical drug development.